Anavex Life Sciences (NASDAQ:AVXL) Earns Buy Rating from D. Boral Capital

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $46.00 target price on the biotechnology company’s stock. D. Boral Capital’s target price would suggest a potential upside of 374.23% from the stock’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, January 21st.

Anavex Life Sciences Price Performance

Shares of AVXL stock opened at $9.70 on Tuesday. The stock’s 50 day simple moving average is $9.98 and its two-hundred day simple moving average is $7.51. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $14.44. The company has a market cap of $822.72 million, a PE ratio of -18.65 and a beta of 0.70.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.03. Equities research analysts expect that Anavex Life Sciences will post -0.73 EPS for the current year.

Hedge Funds Weigh In On Anavex Life Sciences

Large investors have recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in Anavex Life Sciences by 70.4% in the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after purchasing an additional 64,101 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Anavex Life Sciences by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 14,892 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Anavex Life Sciences by 483.8% in the 2nd quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 386,537 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Anavex Life Sciences by 6.7% in the 3rd quarter. Franklin Resources Inc. now owns 58,557 shares of the biotechnology company’s stock valued at $317,000 after purchasing an additional 3,674 shares during the period. Finally, Nwam LLC acquired a new stake in shares of Anavex Life Sciences in the third quarter valued at approximately $5,172,000. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.